TG Therapeutics Should Increase Their Share Buyback Authorization Immediately

by Biotech Newsroom


Word count: 2,076 words, Reading Time: 10 minutes

Last week, at the end of my article, I wrote about TG Therapeutics (behind the paywall, pay $10/month!) but I don’t feel I gave them the credit they earned.

They deserve a full article this week.

This is a company that is operating at an extremely high level and I wanted to take this week to single out why they are different than most other commercial-stage companies and why I included them last week despite having a noticeably higher Price/Sales multiple than the other names I wrote about….



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC